Arbutus Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Arbutus Biopharma Corporation (ABUS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-69.92-72.85-69.46-76.25-63.75-153.72-57.06
Depreciation & Amortization1.381.401.432.801.981.752.18
Deferred Income Tax0.000.000.000.000.00-12.66-4.28
Stock Based Compensation8.999.307.186.426.160.000.00
Change in Working Capital-2.83-18.2329.240.930.43-2.23-4.28
Change in Accounts Receivable-0.63-0.42-0.450.41-0.110.000.00
Change in Accounts Payable-2.71-5.765.221.911.670.000.00
Change in Other Working Capital1.87-3.342.03-1.39-1.130.000.00
Other Operating Activities0.50-3.34-3.703.170.9896.08-6.90
Net Cash from Operating Activities-64.85-85.94-35.36-69.36-51.44-71.01-67.87
Investing Activities
Capital Expenditures-0.18-1.01-0.510.81-0.230.59-1.11
Acquisitions0.000.072.231.87-2.030.000.00
Purchases of Investments23.13-80.51-74.43-82.22-14.680.000.00
Sales/Maturities of Investments164.64132.2756.00-11.87-12.1828.74-3.01
Other Investing Activities0.000.000.001.870.47-0.170.00
Net Cash from Investing Activities22.9550.77-74.94-10.81-14.9128.34-4.13
Financing Activities
Debt Repayment0.000.000.000.000.000.00-12.00
Common Stock Issued52.0029.8531.810.4686.7518.6066.27
Other Financing Activities7.870.0031.30134.670.0018.550.00
Net Cash from Financing Activities52.0030.6531.81137.2486.7537.4655.65
Summary
Effect of Forex Changes on Cash-0.050.03-0.020.010.060.07-1.00
Net Change in Cash10.05-4.52-78.5157.0720.45-5.14-16.35
Cash at Beginning of Period26.2930.78109.2852.2531.8036.9454.29
Cash at End of Period36.3326.2930.78109.3352.2731.8036.94
Free Cash Flow-65.03-86.94-35.87-70.17-51.67-71.58-69.00
Supplemental Disclosures
Interest Paid0.000.000.000.000.000.000.10